References
- Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25–146.
- Taylor J, Walshe FMR. Selected Writings of John Hughlings Jackson on Epilepsy and Eplileptiform Convulsions. London: Hodder & Stoughton; 1931.
- Rowan AJ. Epilepsy in older adults. Common morbidities influence development, treatment strategies, and expected outcomes. Geriatrics. 2005;60(12):30–2, 4.
- Chang C-S, Liao C-H, Lin -C-C, et al. Patients with epilepsy are at an increased risk of subsequent stroke: a population-based cohort study. Seizure. 2014;23(5):377–381.
- Cleary P, Shorvon S, Tallis R. Late-onset seizures as a predictor of subsequent stroke. Lancet (London, England). 2004;363(9416):1184–1186.
- Tellez-Zenteno JF, Matijevic S, Wiebe S. Somatic comorbidity of epilepsy in the general population in Canada. Epilepsia. 2005;46(12):1955–1962.
- Strine TW, Kobau R, Chapman DP, et al. Psychological distress, comorbidities, and health behaviors among U.S. adults with seizures: results from the 2002 National Health Interview Survey. Epilepsia. 2005;46(7):1133–1139.
- Cockerell OC, Johnson AL, Sander JW, et al. Mortality from epilepsy: results from a prospective population-based study. Lancet (London, England). 1994;344(8927):918–921.
- Ding D, Wang W, Wu J, et al. Premature mortality in people with epilepsy in rural China: a prospective study. Lancet Neurol. 2006;5(10):823–827.
- Nilsson L, Tomson T, Farahmand BY, et al. Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia. 1997; 38(10):1062–1068.
- Jallon P. Mortality in patients with epilepsy. Curr Opin Neurol. 2004;17(2):141–146.
- Mohanraj R, Norrie J, Stephen LJ, et al. Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. Lancet Neurol. 2006;5(6):481–487.
- Barolin GS. The cerebrovascular epilepsies. Electroencephalogr Clin Neurophysiol Suppl. 1982;21(35):287–295.
- Selassie AW, Wilson DA, Martz GU, et al. Epilepsy beyond seizure: a population-based study of comorbidities. Epilepsy Res. 2014;108(2):305–315.
- Gaitatzis A, Carroll K, Majeed A, et al. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia. 2004;45(12):1613–1622.
- Nuyen J, Schellevis FG, Satariano WA, et al. Comorbidity was associated with neurologic and psychiatric diseases: a general practice-based controlled study. J Clin Epidemiol. 2006;59(12):1274–1284.
- Shinton RA, Gill JS, Zezulka AV, et al. The frequency of epilepsy preceding stroke. Case-control study in 230 patients. Lancet (London, England). 1987;1(8523):11–13.
- Janszky I, Hallqvist J, Tomson T, et al. Increased risk and worse prognosis of myocardial infarction in patients with prior hospitalization for epilepsy–the Stockholm Heart Epidemiology Program. Brain: J Neurol. 2009;132(Pt 10):2798–2804.
- Wannamaker BB, Wilson DA, Malek AM, et al. Stroke after adult-onset epilepsy: a population-based retrospective cohort study. Epilepsy Behav: E&B. 2015;43:93–99.
- Hsieh CY, Lai EC, Yang YH, et al. Comparative stroke risk of antiepileptic drugs in patients with epilepsy. Epilepsia. 2013;54(1):172–180.
- Jeon SB, Parikh G, Choi HA, et al. Acute cerebral microbleeds in refractory status epilepticus. Epilepsia. 2013;54(5):e66–8.
- Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. The. Lancet Neurol. 2011;10(5):446–456.
- Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314–319.
- Olesen JB, Abildstrom SZ, Erdal J, et al. Effects of epilepsy and selected antiepileptic drugs on risk of myocardial infarction, stroke, and death in patients with or without previous stroke: a nationwide cohort study. Pharmacoepidemiol Drug Saf. 2011;20(9):964–971.
- Dregan A, Charlton J, Wolfe CD, et al. Is sodium valproate, an HDAC inhibitor, associated with reduced risk of stroke and myocardial infarction? A nested case-control study. Pharmacoepidemiol Drug Saf. 2014;23(7):759–767.
- Chuang YC, Chuang HY, Lin TK, et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia. 2012;53(1):120–128.
- Hamed SA. Atherosclerosis in epilepsy: its causes and implications. Epilepsy Behav: E&B. 2014;41:290–296.
- Malinska D, Kulawiak B, Kudin AP, et al. Complex III-dependent superoxide production of brain mitochondria contributes to seizure-related ROS formation. Biochim Biophys Acta. 2010;1797(6–7):1163–1170.
- Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84(4):1381–1478.
- Mintzer S, Skidmore CT, Abidin CJ, et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol. 2009;65(4):448–456.
- Koba S, Hirano T. Dyslipidemia and atherosclerosis. Nihon Rinsho Jpn J Clin Med. 2011;69(1):138–143.
- Kim DW, Lee SY, Shon YM, et al. Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy. Epilepsia. 2013;54(10):e146–9.
- Schwaninger M, Ringleb P, Annecke A, et al. Elevated plasma concentrations of lipoprotein(a) in medicated epileptic patients. J Neurol. 2000;247(9):687–690.
- Hamed SA, Hamed EA, Hamdy R, et al. Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res. 2007;74(2–3):183–192.
- Bramswig S, Sudhop T, Luers C, et al. Lipoprotein(a) concentration increases during treatment with carbamazepine. Epilepsia. 2003;44(3):457–460.
- Phabphal K, Limapichat K, Sathirapanya P, et al. Characterization of glucose homeostasis and lipid profile in adult, seizure-free, epileptic patients in Asian population. Euro J Neurol. 2012;19(9):1228–1234.
- Eiris J, Novo-Rodriguez MI, Del Rio M, et al. The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res. 2000;41(1):1–7.
- Manimekalai K, Visakan B, Salwe KJ, et al. Evaluation of effect of antiepileptic drugs on serum lipid profile among young adults with Epilepsy in a Tertiary Care Hospital in Pondicherry. JCDR. 2014;8(8):Hc05–9.
- Yis U, Dogan M. Effects of oxcarbazepine treatment on serum lipids and carotid intima media thickness in children. Brain Dev. 2012;34(3):185–188.
- Franzoni E, Marchiani V, Cecconi I, et al. Preliminary report on effects of oxcarbazepine-treatment on serum lipid levels in children. Euro J Neurol. 2006;13(12):1389–1391.
- El-Farahaty RM, El-Mitwalli A, Azzam H, et al. Atherosclerotic effects of long-term old and new antiepileptic drugs monotherapy: a cross-sectional comparative study. J Child Neurol. 2015;30(4):451–457.
- Svalheim S, Luef G, Rauchenzauner M, et al. Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine. Acta Neurol Scand Suppl. 2010;122(190):30–33.
- Mintzer S, Skidmore CT, Rankin SJ, et al. Conversion from enzyme-inducing antiepileptic drugs to topiramate: effects on lipids and C-reactive protein. Epilepsy Res. 2012;98(1):88–93.
- Eckel RH, Barouch WW, Ershow AG. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease. Circulation. 2002;105(24):2923–2928.
- Katsiki N, Mikhailidis DP, Nair DR. The effects of antiepileptic drugs on vascular risk factors: a narrative review. Seizure. 2014;23(9):677–684.
- Isojarvi JI, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol. 1996;39(5):579–584.
- Verrotti A, Manco R, Agostinelli S, et al. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia. 2010;51(2):268–273.
- Zeng K, Wang X, Xi Z, et al. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients. Clin Neurol Neurosurg. 2010;112(4):291–295.
- Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs. 2003;17(11):781–791.
- Apovian CM, Aronne LJ. Zonisamide for weight reduction in obese adults. JAMA. 2013;310(6):637–638.
- Janousek J, Barber A, Goldman L, et al. Obesity in adults with epilepsy. Epilepsy Behav: E&B. 2013;28(3):391–394.
- Pylvanen V, Knip M, Pakarinen AJ, et al. Fasting serum insulin and lipid levels in men with epilepsy. Neurology. 2003;60(4):571–574.
- Roy Chengappa KN, Levine J, Rathore D, et al. Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur psychiatry: J Assoc Eur Psychiatrists. 2001;16(3):186–190.
- Ashjazadeh N, Fathi M, Shariat A. Evaluation of homocysteine level as a risk factor among patients with Ischemic stroke and its subtypes. Iran J Med Sci. 2013;38(3):233–239.
- Linnebank M, Moskau S, Semmler A, et al. Antiepileptic drugs interact with folate and vitamin B12 serum levels. Ann Neurol. 2011;69(2):352–359.
- Belcastro V, Striano P, Gorgone G, et al. Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. Epilepsia. 2010;51(2):274–279.
- Keenan N, Sadlier LG, Wiltshire E. Vascular function and risk factors in children with epilepsy: associations with sodium valproate and carbamazepine. Epilepsy Res. 2014;108(6):1087–1094.
- Elliott JO, Jacobson MP, Haneef Z. Cardiovascular risk factors and homocysteine in epilepsy. Epilepsy Res. 2007;76(2–3):113–123.
- Sener U, Zorlu Y, Karaguzel O, et al. Effects of common anti-epileptic drug monotherapy on serum levels of homocysteine, vitamin B12, folic acid and vitamin B6. Seizure. 2006;15(2):79–85.
- Talaat FM, Kamel T, Rabah AM, et al. Epilepsy and antiepileptic drugs: risk factors for atherosclerosis. Int J Neurosci. 2015;125(7):507–511.
- Sankhyan N, Gulati S, Hari S, et al. Noninvasive screening for preclinical atherosclerosis in children on phenytoin or carbamazepine monotherapy: a cross sectional study. Epilepsy Res. 2013;107(1–2):121–126.
- Erdemir A, Cullu N, Yis U, et al. Evaluation of serum lipids and carotid artery intima media thickness in epileptic children treated with valproic acid. Brain Dev. 2009;31(10):713–716.
- Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25(1):39–42.
- Maesaka JK, Fishbane S. Regulation of renal urate excretion: a critical review. Am J Kidney Dis: Official J Nat Kidney Foundation. 1998;32(6):917–933.
- Ring HA, Heller AJ, Marshall WJ, et al. Plasma uric acid in patients receiving anticonvulsant monotherapy. Epilepsy Res. 1991;8(3):241–244.
- Ridker PM, Haughie P. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J Inves Med: Official Publ Am Fed Clin Res. 1998;46(8):391–395.
- Tan TY, Lu CH, Chuang HY, et al. Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia. 2009;50(6):1579–1586.
- Spacilova J, Limanova Z, Aschermann M. Subclinical hypothyroidism with emphasis on the cardiovascular system. Cas Lek Cesk. 2003;142(11):643–647.
- Isojarvi JI, Turkka J, Pakarinen AJ, et al. Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy. Epilepsia. 2001;42(7):930–934.
- Hamed SA, Hamed EA, Kandil MR, et al. Serum thyroid hormone balance and lipid profile in patients with epilepsy. Epilepsy Res. 2005;66(1–3):173–183.
- Yilmaz U, Yilmaz TS, Akinci G, et al. The effect of antiepileptic drugs on thyroid function in children. Seizure. 2014;23(1):29–35.
- Zsurka G, Kunz WS. Mitochondrial dysfunction and seizures: the neuronal energy crisis. Lancet Neurol. 2015;14(9):956–966.
- Bleck TP. Seven questions about stroke and epilepsy. Epilepsy Curr/Am Epilepsy Soc. 2012;12(6):225–228.
- Elliott JO, Lu B, Moore JL, et al. Exercise, diet, health behaviors, and risk factors among persons with epilepsy based on the California Health Interview Survey, 2005. Epilepsy Behav: E&B. 2008;13(2):307–315.
- Elliott JO, Moore JL, Lu B. Health status and behavioral risk factors among persons with epilepsy in Ohio based on the 2006 behavioral risk factor surveillance system. Epilepsy Behav: E&B. 2008;12(3):434–444.
- Kobau R, DiIorio CA, Price PH, et al. Prevalence of epilepsy and health status of adults with epilepsy in Georgia and Tennessee: Behavioral risk factor surveillance system, 2002. Epilepsy Behav: E&B. 2004;5(3):358–366.
- Kobau R, Zahran H, Grant D, et al. Prevalence of active epilepsy and health-related quality of life among adults with self-reported epilepsy in California: California Health Interview Survey, 2003. Epilepsia. 2007;48(10):1904–1913.
- Tikk K, Sookthai D, Monni S, et al. Primary preventive potential for stroke by avoidance of major lifestyle risk factors: the European prospective investigation into cancer and nutrition-Heidelberg cohort. Stroke. 2014;45(7):2041–2046.
- Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368(4):341–350.
- Peters SA, Huxley RR, Woodward M. Smoking as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 81 cohorts, including 3,980,359 individuals and 42,401 strokes. Stroke. 2013;44(10):2821–2828.
- Hsieh FI, Chiou HY. Stroke: morbidity, risk factors, and care in taiwan. J Stroke. 2014;16(2):59–64.
- Paraskevas KI, Bessias N, Papas TT, et al. Do different vascular risk factors affect all arteries equally? Angiology. 2008;59(4):397–401.
- Doonan RJ, Hausvater A, Scallan C, et al. The effect of smoking on arterial stiffness. Hypertens Res: Official J Jpn Soc Hypertens. 2010;33(5):398–410.
- O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (London, England). 2010;376(9735):112–123.
- McDonnell MN, Hillier SL, Hooker SP, et al. Physical activity frequency and risk of incident stroke in a national US study of blacks and whites. Stroke. 2013;44(9):2519–2524.
- Seidenberg M, Pulsipher DT, Hermann B. Association of epilepsy and comorbid conditions. Future Neurol. 2009;4(5):663–668.
- Ng SK, Hauser WA, Brust JC, et al. Hypertension and the risk of new-onset unprovoked seizures. Neurology. 1993;43(2):425–428.
- Hesdorffer DC, Hauser WA, Annegers JF, et al. Severe, uncontrolled hypertension and adult-onset seizures: a case-control study in Rochester, Minnesota. Epilepsia. 1996;37(8):736–741.
- Caccamo D, Condello S, Gorgone G, et al. Screening for C677T and A1298C MTHFR polymorphisms in patients with epilepsy and risk of hyperhomocysteinemia. Neuromolecular Med. 2004;6(2–3):117–126.
- Belcastro V, Gaetano G, Italiano D, et al. Antiepileptic drugs and MTHFR polymorphisms influence hyper-homocysteinemia recurrence in epileptic patients. Epilepsia. 2007;48(10):1990–1994.
- Ni Chroinin D, Callaly EL, Duggan J, et al. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population Stroke Study. Stroke. 2011;42(4):1021–1029.
- Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53(6):743–751.
- Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (London, England). 2003;361(9374):2005–2016.
- Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556–1565.
- Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078–2087.
- Ni Chroinin D, Asplund K, Asberg S, et al. Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke. 2013;44(2):448–456.
- Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8(5):453–463.
- Etminan M, Samii A, Brophy JM. Statin use and risk of epilepsy: a nested case-control study. Neurology. 2010;75(17):1496–1500.
- Pugh MJ, Knoefel JE, Mortensen EM, et al. New-onset epilepsy risk factors in older veterans. J Am Geriatr Soc. 2009;57(2):237–242.
- Earnest CP, Wood KA, Church TS. Complex multivitamin supplementation improves homocysteine and resistance to LDL-C oxidation. J Am Coll Nutr. 2003;22(5):400–407.
- Volpe SL, Schall JI, Gallagher PR, et al. Nutrient intake of children with intractable epilepsy compared with healthy children. J Am Diet Assoc. 2007;107(6):1014–1018.
- Hamed SA, Nabeshima T. The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins. J Pharmacol Sci. 2005;98(4):340–353.
- Belcastro V, Striano P. Antiepileptic drugs, hyperhomocysteinemia and B-vitamins supplementation in patients with epilepsy. Epilepsy Res. 2012;102(1–2):1–7.
- Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288(19):2432–2440.
- Katsiki N, Manes C. Is there a role for supplemented antioxidants in the prevention of atherosclerosis? Clin Nutr. 2009;28(1):3–9.
- Willett WC. The Mediterranean diet: science and practice. Public Health Nutr. 2006;9(1a):105–110.
- Tse LA, Fang XH, Wang WZ, et al. Incidence of ischaemic and haemorrhagic stroke and the association with smoking and smoking cessation: a 10-year multicentre prospective study in China. Public Health. 2012;126(11):960–966.
- Wolf PA, D’Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for stroke. The Framingham study. JAMA. 1988;259(7):1025–1029.
- Honjo K, Iso H, Tsugane S, et al. The effects of smoking and smoking cessation on mortality from cardiovascular disease among Japanese: pooled analysis of three large-scale cohort studies in Japan. Tob Control. 2010;19(1):50–57.
- Lavoie FW, Harris TM. Fatal nicotine ingestion. J Emerg Med. 1991;9(3):133–136.
- Rong L, Frontera AT Jr., Benbadis SR. Tobacco smoking, epilepsy, and seizures. Epilepsy Behav: E&B. 2014;31:210–218.
- Lackland DT, Voeks JH. Metabolic syndrome and hypertension: regular exercise as part of lifestyle management. Curr Hypertens Rep. 2014;16(11):492.
- Wendel-Vos GC, Schuit AJ, Feskens EJ, et al. Physical activity and stroke. A meta-analysis of observational data. Inte J Epidemiol. 2004;33(4):787–798.
- Krarup LH, Truelsen T, Gluud C, et al. Prestroke physical activity is associated with severity and long-term outcome from first-ever stroke. Neurology. 2008;71(17):1313–1318.
- Nakken KO. Physical exercise in outpatients with epilepsy. Epilepsia. 1999;40(5):643–651.
- Howard GM, Radloff M, Sevier TL. Epilepsy and sports participation. Curr Sports Med Rep. 2004;3(1):15–19.
- Larsson SC, Akesson A, Wolk A. Overall diet quality and risk of stroke: a prospective cohort study in women. Atherosclerosis. 2014;233(1):27–29.
- Kurth T, Moore SC, Gaziano JM, et al. Healthy lifestyle and the risk of stroke in women. Arch Intern Med. 2006;166(13):1403–1409.
- He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. Lancet (London, England). 2006;367(9507):320–326.
- Kontogianni MD, Panagiotakos DB. Dietary patterns and stroke: a systematic review and re-meta-analysis. Maturitas. 2014;79(1):41–47.
- Payne NE, Cross JH, Sander JW, et al. The ketogenic and related diets in adolescents and adults–a review. Epilepsia. 2011;52(11):1941–1948.
- Pfeifer HH, Thiele EA. Low-glycemic-index treatment: a liberalized ketogenic diet for treatment of intractable epilepsy. Neurology. 2005;65(11):1810–1812.
- Rizkalla SW, Taghrid L, Laromiguiere M, et al. Improved plasma glucose control, whole-body glucose utilization, and lipid profile on a low-glycemic index diet in type 2 diabetic men: a randomized controlled trial. Diabetes Care. 2004;27(8):1866–1872.
- Mula M. Topiramate and cognitive impairment: evidence and clinical implications. Therapeutic Adv Drug Saf. 2012;3(6):279–289.